A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Summary

The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.

Timeline

Start

2020-09-04

Primary completion

2021-12-22

Completion

2021-12-22

Outcome

Met primary endpoint

paper TAS-303 had superior efficacy to placebo, with a least squares mean percent change in mean SUIEF of -57.7% vs -46.9%, respectively PMID 38979756 ↗

Publications

• Takahashi S, Kato K, Yokoyama O, Takei M, Gotoh M. Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. J Urol. 2024 Aug;212(2):267-279. doi: 10.1097/JU.0000000000004024. Epub 2024 Jul 9.

Drugs

Indications